Please assess the completion status of the following clinical trial:

Trial Title: Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of PMF or post-ET/PV MF as per revised World Health Organization (WHO) criteria (Section 16.4, Appendix 3).~* High-risk or Intermediate-2 risk MF (as defined by the International Prognostic Scoring System \[IPSS\]; Section 16.6, Appendix 5); or Intermediate-1 risk MF (IPSS) associated with symptomatic splenomegaly/hepatomegaly and/or unresponsive to available therapy.~* Must be at least 18 years of age with life expectancy of ≥ 12 weeks.~* Must be able to provide informed consent and be willing to sign an informed consent form.~* Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 (Section 16.3, Appendix 2).~* Must have evidence of acceptable organ function within 7 days of initiating study drug as evidenced by the following:~* AST or ALT less than or equal 2.5 x upper limit of normal (ULN) (or less than or equal to 5 x ULN if in the investigator's opinion the elevation is due to extramedullary hematopoiesis)~* Direct Bilirubin less than or equal to 2.0 x ULN~* Serum creatinine less than or equal to 2.5 x ULN~* Absolute neutrophil count ≥ 500/µL~* Platelet count ≥ 50,000/µL~* Females of childbearing potential must have a negative pregnancy test within 4 days of initiating study drug.~Exclusion Criteria:~* Any chemotherapy (e.g., hydroxyurea), immunomodulatory drug therapy (e.g., thalidomide), immunosuppressive therapy, corticosteroids \>10 mg/day prednisone or equivalent, or growth factor treatment (e.g., erythropoietin) within 14 days prior to initiation of study drug.~* Incomplete recovery from major surgery within four weeks of study entry.~* Radiation therapy within four weeks of study entry.~* Women of childbearing potential, unless surgically sterile for at least 3 months (i.e., hysterectomy), OR postmenopausal for at least 12 months (FSH \> 30 U/mL), OR unless they agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through end of study. Permitted methods for preventing pregnancy must be communicated to study subjects and their understanding confirmed.~* Men who partner with a woman of childbearing potential, unless they agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through to the end of study. Permitted methods for preventing pregnancy must be communicated to study subjects and their understanding confirmed.~* Females who are pregnant or are currently breastfeeding.~* Known positive status for HIV.~* Positive serologic testing for hepatitis B (HBsAg and HBcAb total) and hepatitis C (anti-HCV)~* Diagnosis of another malignancy unless free of disease for at least three years following therapy with curative intent. Patients with early-stage basal cell or squamous cell skin cancer, cervical intraepithelial neoplasia, cervical carcinoma in situ or superficial bladder cancer may be eligible participate at the Investigator's discretion.~* Any acute active infection.~* Cardiac dysrhythmias requiring treatment, or prolongation of the QTc (Fridericia) interval to \>480 at pre-study screening, unless attributable to pre-existing bundle branch block.~* Presence of ≥ grade 2 peripheral neuropathy.~* Uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4), uncontrolled or unstable angina, myocardial infarction, cerebrovascular accident, or pulmonary embolism within 3 months prior to initiation of study drug.~* Uncontrolled intercurrent illness or any concurrent condition that, in the Investigator's opinion, would jeopardize the safety of the patient or compliance with the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Momelotinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete